UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 OMB APPROVAL
-----------------
OMB Number:3235-0058
-----------------
Expires:January 31, 2002
-----------------
Estimated
average burden
hours per
response....2.50
Form 12b-25
NOTIFICATION OF LATE FILING
SEC File Number
-----------------
CUSIP Number
-----------------
(Check one): [ X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ]
Form 10-Q [ ] Form N-SAR
For Period Ended: June 30, 2003 [ ] Transition Report on Form 10-K [ ]
Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition
Report on Form 10-Q [ ] Transition Report on Form N-SAR For Period Ended:
===============================================================================
Read Attached Instruction (on back page) Before Preparing Form. Please Print
or Type.
===============================================================================
===============================================================================
Nothing in this form shall be construed to imply that the Commission has
verified any
information contained herein.
===============================================================================
-------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
Corgenix Medical Corporation
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Full Name of Registrant
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Former Name if Applicable
12061 Tejon Street
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Westminster, CO 80234
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
City, State and Zip Code
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[ X ] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or expense;
Persons who potentially are to respond to the collection of
information contained in this form are not required to respond unless
the form displays a currently valid OMB control number.
[ X ] (b) The subject annual or semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report of transition report on Form
10-Q, or portion thereof will be filed on or before the fifth;
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State in reasonable detail the reasons why the Forms 10-K, 20-F, 11-K, 10-Q or
N-SAR, or the transition report portion thereof, could not be filed within the
prescribed time period.
The Company has previously announced a proposed merger with Genesis Bioventures,
Inc. and plans to obtain equity financing for the merged company in connection
with that transaction. Completion of that financing would have a significant
impact upon the Company's liquidity. If the merger and the financing are not
completed, the Company anticipates the need to obtain other funding or consider
the need to restructure or implement a strategic redirection of the Company's
business. The Company is in the process of preparing updated financing models
and a revised budget that address the above scenarios. The Company cannot
complete this work within the prescribed time for filing the subject report
without unreasonable efforts or expense. KPMG, the Company's independent
accountants, has informed the Company that in view of the uncertainty of the
proposed financing and absent budgetary information to consider the effect of
the above scenarios, its report on the financial statements of the Company for
the fiscal year ended June 30, 2003, will include an explanatory paragraph
referencing the Company's ability to continue as a going concern. The Company
expects that the information being prepared may have a significant bearing on
disclosures in the subject report about its financial viability and its status
as a going concern. The Company expects to file the report no later than October
14, 2003.
(Attach Extra Sheets if Needed)
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
------------------------------------------------------------------
William H. Critchfield (303) 453-8903
------------------------------------------------------------------
------------------------------------------------------------------
(Name) (Area (Telephone Code) Number)
------------------------------------------------------------------
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
[ X ] Yes [ ] No
---------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? [ ]
Yes [ X ] No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
----------------------------------------------------
Corgenix Medical Corporation
----------------------------------------------------
----------------------------------------------------
(Name of Registrant as Specified in Charter)
----------------------------------------------------
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: September 30, 2003 By: /s/ William H. Critchfield
------------------
--------------------------
Chief Financial Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
ATTENTION
================================================================
================================================================
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
================================================================
General Instructions
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules
and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information contained in or
filed with the form will be made a matter of public record in the Commission
files.
3. A manually signed copy of the form and amendments thereto shall be filed with
each national securities exchange on which any class of securities of the
registrant is registered.
4. Amendments to the notifications must also be filed on form 12b-25 but need
not restate information that has been correctly furnished. The form shall be
clearly identified as an amended notification.
5. Electronic filers. This form shall not be used by electronic filers unable to
timely file a report solely due to electronic difficulties. Filers unable to
submit a report within the time period prescribed due to difficulties in
electronic filing should comply with either Rule 201 or Rule 202 of
Regulation S-T ("232.201 or "232.202 of this chapter) or apply for an
adjustment in filing date pursuant to Rule 13(b) of Regulation S-T
("232.13(b) of this chapter).